City page
Lund biotech and pharma directory
Lund is the Swedish anchor of Medicon Valley — the cross-border life-sciences cluster connecting southern Sweden with Copenhagen. Compact but unusually deep: Lund University drives translational research, Medicon Village (the former AstraZeneca campus, now a 2,500-employee biotech park) hosts dozens of operators including SAGA Diagnostics (cancer liquid biopsy), Camurus (drug delivery), Probi (probiotics), and many emerging biotech. The Skåne region around Lund-Malmö is one of Europe's densest biomedical clusters per capita.
Where does this city read strongest?
Therapeutics (9), Infrastructure anchor (1), and Diagnostics (1). Most visible records: Diaprost AB, SAGA Diagnostics, and Hamlet BioPharma.
Which standards and public evidence are already visible?
GMP (1) and GLP (1). Latest review: 24 April 2026. Review cycle: April 2026.
Why does this city matter?
This page brings visible companies and infrastructure records into one practical view of Lund.
By category
Lund by category
Jump into a category page filtered to this country only.
Full list
Lund biotech and pharma directory
11 city records currently match the active filter.
Current review cycle
Diaprost AB
LundSwedenTherapeutics
Privately held Lund developer of humanized anti-PSA and anti-hK2 antibodies for radiolabeled theranostic programs in prostate cancer, licensed in part to Radiopharm Theranostics.
- Lead
- Johan DrottFounder and Chief Executive Officer
- Scale
- Preclinical to early-clinical, partner-led
Current review cycle
SAGA Diagnostics
LundSwedenDiagnostics
Lund-based liquid biopsy developer running tumor-informed molecular residual disease (MRD) detection for solid cancers, with a commercial Pathlight Breast MRD test launched out of a CLIA-certified North Carolina laboratory.
- Lead
- Peter CollinsChief Executive Officer
- Scale
- Clinical diagnostic service delivery
Current review cycle
Hamlet BioPharma
LundSwedenTherapeutics
Lund therapeutics company developing cancer and infection treatments, including bladder-cancer and anti-infective programs, from a Swedish listed-company base.
- Lead
- Jakob TestadChief Executive Officer
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Medicon Village
LundSwedenInfrastructure anchor
Lund life-science campus and innovation cluster combining laboratories, offices, incubator activity, events, and ecosystem infrastructure at the former AstraZeneca site.
- Lead
- Petter HartmanCEO, Medicon Village Innovation
- Scale
- Regional life-science infrastructure platform
Current review cycle
Asgard Therapeutics
LundSwedenTherapeutics
Lund immunotherapy company developing direct cell-reprogramming approaches for cancer treatment from the Medicon Village ecosystem.
- Lead
- Cristiana PiresCo-Founder and CEO
- Scale
- Early-stage therapeutics platform
Current review cycle
Xintela
LundSwedenTherapeutics
Lund biopharma company developing stem-cell therapies and targeted oncology assets from Medicon Village, with clinical and GMP-linked advanced-therapy operations.
- Lead
- Evy Lundgren-AkerlundChief Executive Officer
- Scale
- Clinical-stage cell-therapy platform
Current review cycle
Alligator Bioscience
LundSwedenTherapeutics
Lund clinical-stage biotech company developing tumor-directed immuno-oncology antibodies, with mitazalimab and related CD40-focused programs at its Swedish headquarters.
- Lead
- Soren BregenholtCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Cantargia
LundSwedenTherapeutics
Lund antibody-therapeutics company developing oncology and inflammation drug candidates from a Swedish clinical-stage biotech platform.
- Lead
- Damian MarronCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Active Biotech
LundSwedenTherapeutics
Lund therapeutics company developing oncology and immunology drug candidates from a Swedish clinical-stage biotech platform.
- Lead
- Helen TornqvistCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Hansa Biopharma
LundSwedenTherapeutics
Lund biopharma company developing enzyme-based therapies for transplant medicine, rare immunological diseases, and desensitization treatment.
- Lead
- Soren TulstrupPresident and CEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Camurus
LundSwedenTherapeutics
Lund therapeutic-development anchor built around long-acting drug-delivery technologies and late-stage specialty-pharma execution.
- Lead
- Fredrik TibergPresident and Chief Executive Officer
- Scale
- Late-stage and commercial specialty pharma
FAQ
Frequently asked questions
- What is Medicon Village?
- Medicon Village is a 2,500-employee biotech and life-sciences park in Lund, Sweden, built on the former AstraZeneca campus after the company exited Lund in 2010. It now hosts dozens of biotech operators, research groups, and startups, anchored by Lund University and integrated with the broader Medicon Valley cluster.
- What companies are in Lund biotech?
- SAGA Diagnostics (cancer liquid biopsy, ctDNA), Camurus (drug delivery — long-acting injectable formulations), Probi (probiotics), plus a long tail of mid-cap biotech and translational spinouts at Medicon Village. The University-affiliated discovery pipeline feeds the cluster steadily.
- How does Lund compare to Stockholm or Gothenburg?
- Lund = compact Medicon Valley anchor (Lund University + Medicon Village) with very high density per capita. Stockholm = larger urban biotech with Karolinska + SciLifeLab. Gothenburg = AstraZeneca legacy + western Sweden cluster. The three are complementary; Lund punches above its weight relative to size.
Related briefs
Briefs that mention Lund
Viral Vector CDMO Europe 2026: AAV, Adenovirus, Lentivirus
Where to manufacture viral vectors in Europe in 2026 — FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, Fuse Vectors, IDT Biologika — and how the European viral vector CDMO layer is structured.
Open briefNordic Biotech Landscape 2026: Denmark, Sweden, Finland, Norway
A practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefCell & Gene Therapy Europe 2026: CAR-T, Stem Cell, ATMP, Regenerative
A practical map of the European cell and gene therapy landscape in 2026 — CAR-T and TCR-T therapeutics, stem-cell and regenerative ATMPs, tissue engineering, plus the viral-vector CDMO and tools supply chain — across 26 operators in the directory.
Open briefNext step
Read the city, then widen the view.
Use country and regional pages for wider context, and the company suggestion form for new candidate records.